文献速递青光眼

晚期青光眼治疗研究(TAGS)的两年视野结局

Two-Year Visual Field Outcomes of the Treatment of Advanced Glaucoma Study (TAGS).
PubMed 文献 · Am J Ophthalmol · 2022-10-10

TAGS研究的事后分析比较了初始接受小梁切除术与药物治疗的晚期开角型青光眼患者2年视野进展速率。药物治疗组有更多眼出现进展,但差异无统计学意义。

要点

  • 药物治疗组平均进展速率为-0.59 dB/年,小梁切除术组为-0.40 dB/年,差异无统计学意义(贝叶斯P值=0.353)。
  • 药物治疗组有更多眼出现进展,但差异无统计学意义。
  • 两组2年平均视野进展速率无显著差异。

核心结论

  • 2年平均视野进展速率在小梁切除术先治疗组与药物治疗先治疗组之间无显著差异(贝叶斯P值=0.353)。

研究设计与样本

  • TAGS研究的事后分析,基于一项双臂、多中心、随机对照临床试验的视野数据。
  • 纳入英国27个中心新诊断的至少1只眼为晚期开角型青光眼的453例患者,随机分为小梁切除术组(n=227)或药物治疗组(n=226),随访2年,在基线、4、12和24个月进行2次24-2视野测试。
  • 分析纳入基线及至少2个其他时间点有可靠视野(假阳性率<15%)的参与者,共分析小梁切除术先治疗组211只眼和药物治疗先治疗组203只眼。

主要发现

  • 药物治疗先治疗组平均进展速率为-0.59 dB/年(95%可信区间[-0.88, -0.31]),小梁切除术先治疗组为-0.40 dB/年(95%可信区间[-0.67, -0.13])。
  • 两组平均进展速率差异无统计学意义(贝叶斯P值=0.353)。
  • 药物治疗先治疗组有更多眼出现进展,但差异无统计学意义。

关键数值与推荐

  • 视野进展速率使用分层贝叶斯模型分析。
  • 采用生存分析比较每只眼从基线进展超过特定切点(0.5、1、1.5和2 dB)的时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: to compare visual field (VF) progression between the 2 arms of the Treatment of Advanced Glaucoma Study (TAGS). DESIGN: Post hoc analysis of VF data from a 2-arm, multicenter, randomized controlled clinical trial. METHODS: A total of 453 patients with newly diagnosed advanced open-angle glaucoma in at least 1 eye from 27 centers in the United Kingdom were randomized to either trabeculectomy (n = 227) or medication in their index eye (n = 226) and followed-up for 2 years with 2 24-2 VF tests at baseline, 4, 12, and 24 months. Data were analyzed for participants with a reliable VF (false positive rate < 15%) at baseline and at least 2 other time points. Average difference in rate of progression (RoP) was analyzed using a hierarchical Bayesian model. Time for each eye to progress from baseline beyond specific cut-offs (0.5, 1, 1.5, and 2 dB) was compared using survival analysis. RESULTS: This study analyzed 211 eyes in the trabeculectomy first arm and 203 eyes in the medication first arm. The average RoP (estimate [95% credible intervals]) was -0.59 [-0.88, -0.31] dB/year in the medication first arm and -0.40 [-0.67, -0.13] dB/year in the trabeculectomy first arm. The difference was not significant (Bayesian P-value = .353). More eyes progressed in the medication first arm, but this difference was not significant. CONCLUSIONS: There was no significant difference in the average RoP at 2 years.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Montesano G, Ometto G, King A, et al. Two-Year Visual Field Outcomes of the Treatment of Advanced Glaucoma Study (TAGS). Am J Ophthalmol. 2022. PMID: 36228777. doi:10.1016/j.ajo.2022.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。